IMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023
12 Junio 2023 - 7:30AM
IMUNON, Inc. (NASDAQ:
IMNN), a clinical-stage drug-development company focused
on developing non-viral DNA-mediated immunotherapy and
next-generation vaccines, announces that Dr. Corinne Le Goff,
President and Chief Executive Officer, will be participating in a
panel discussion on June 13, 2023 at the Mass General Brigham World
Medical Innovation Forum 2023. The panel will focus on efforts to
drive cell therapy into solid tumors, and Dr. Le Goff will be
highlighting the promise of IMUNON’s DNA therapy in treating
ovarian cancer and potentially other solid tumor types.
Dr. Le Goff will describe the progress with
IMNN-001 (formerly GEN-1), a DNA-based interleukin-12 (IL-12)
immunotherapy currently in Phase 2 clinical development for the
localized treatment of advanced ovarian cancer.
The panel will be moderated by executives from
Mass General Cancer Center and Bank of America Securities. Other
panelists will represent BioNTech, Carisma Therapeutics and Lyell
Immunopharma.
The World Medical Innovation Forum 2023, taking
place in Boston June 12-14, 2023, convenes clinicians and industry
representatives working together to advance patient-benefitting
technologies, and differentiates itself as the one event where
physicians and senior clinical leaders connect with peers across
the medical landscape. This year’s Forum takes a deep dive into
CNS/brain health and oncology, as well as immunology and
inflammation. It brings together global leaders to address the
latest opportunities and challenges in the investment landscape,
key technology developments, manufacturing and regulatory
barriers.
The World Medical Innovation Forum 2023 is
presented by Mass General Brigham and Bank of America.
About IMUNON
IMUNON is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies.
IMUNON has two platform technologies: the
TheraPlas modality for the development of immunotherapies and other
anti-cancer nucleic acid-based therapies, and the PlaCCine modality
for the development of nucleic acid vaccines for infectious
diseases and cancer. The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting preclinical proof-of-concept studies on a nucleic acid
vaccine candidate targeting the SARS-CoV-2 virus to validate its
PlaCCine platform. IMUNON’s platform technologies are based on the
delivery of nucleic acids with novel synthetic delivery systems
that are independent of viral vectors or devices. IMUNON will
continue to leverage these platforms and to advance the
technological frontier of nucleic acid-based products to better
serve patients with difficult-to-treat conditions. For more
information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts: |
|
|
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
and Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Imunon (NASDAQ:IMNN)
Gráfica de Acción Histórica
De May 2023 a May 2024